GSK to buy US cancer treatment firm Nuvalent for $10.6bn

British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one o…

In breve

<article class="opinion default clearfix">

<h2> <a href="https://www.middleeasteye.net/opinion/iran-will-no-longer-accept-endless-talks-it-creating-deterrence-its-own-terms" rel="bookmark"> <span class="field field-title">Iran will no longer accept endless talks.

Contesto

GSK to buy US cancer treatment firm Nuvalent for $10.6bn British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading... According to the collected source material from www.theguardian.com, British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with…

Lettura DEO

Verdetto: publish
Confidenza: 82/100

Deterministic fallback judge output. Libre judge fallback via DeepSeek Gamma.

Categoria: cronaca
Entità: Nuvalent